Novavax, Inc. NVAX R2KR3KPHARMA

Q: What is the current share price of Novavax, Inc. (NVAX)?

As of 2026-09-07 16:24 PDT, Novavax, Inc. (NVAX) trades at $10.22 on NasdaqGS. Its 52-week range is $6.22 to $11.19.

Q: What is the market capitalisation of NVAX?

Novavax, Inc. (NVAX) has a market capitalisation of $1.69B on NasdaqGS.

Q: What is the P/E ratio of NVAX?

NVAX trades at a trailing price-to-earnings (P/E) ratio of -18.25. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is -9.03.

Q: Is NVAX a good stock to buy?

This page provides a data-driven analysis of Novavax, Inc. (NVAX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://www.novavax.com

Company Profile ↓

$10.22

+15.48% 1Y

Mkt Cap$1.69B

P/E-18.25

P/B-9.03

52W High$11.19

52W Low$6.22

Book Value$-0.88

EPS (TTM)$-0.56

Company Overview

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 76.8%.

Steady Revenue Expansion

Revenue has grown at a 78.3% CAGR over the past five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $1.12B (+64.7% YoY); net profit $440.30M.
Trailing 12 Months Year-on-year growth — revenue -76.3%.
5-Year Trend Long-term compounding — revenue CAGR 78.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	78.28%
1 Year:	-76.30%

Stock Price Performance

1 Year:	+15.48%
6 Months:	+2.40%
3 Months:	+7.69%
1 Month:	+32.04%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 80% of range

$6.22 $11.19

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
Golden Cross2d ago
RSI (14)70.68 · Overbought

Price Performance

1M+32.04%

3M+7.69%

6M+2.40%

1Y+15.48%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Healthy ROCE of 76.8%.
Compounding revenue at 78.3% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-18.25

Industry PE

25.17

Forward P/E

-18.45

PEG Ratio

1.32

Book Value

$-0.88

Price to Book

-9.03

P/S

3.17

EV/EBITDA

-8.02

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

78.28%

Profit 5Y

Revenue (YoY)

-76.30%

Earnings (YoY)

Profitability & Returns

ROCE

76.84%

ROE

ROA

-7.02%

Profit Margin

-59.87%

Op Margin

-96.84%

Gross Margin

31.22%

EPS (Latest Qtr)

$-0.32

EPS (TTM)

$-0.56

Balance Sheet & Liquidity

Debt/Equity

Quick Ratio

2.23

Current Ratio

2.33

Debt

$297.32M

Total Assets

$955.58M

Current Assets

$978.28M

Working Capital

$518.33M

Ownership

Promoter Holding

5.06%

Chg in Prom Hold

-0.02%

FII / Inst Holding

69.01%

Chg in FII Hold

-0.03%

Financial Snapshot

Enterprise Value

$1.69B

Total Revenue (TTM)

$413.80M

EBITDA

$-110.95M

Free Cash Flow

$123.02M

Operating Cash Flow

$-36.90M

Shares Outstanding

164.95M

Gross Margin

31.22%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	NVAX Novavax, Inc. R2KR3KPHARMA	10.22	-18.25	$1.69B	0.00%	76.84%	-	78.28%	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,149.36	38.57	$1.02T	0.58%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	275.23	31.97	$663.28B	2.09%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	256.46	72.45	$453.19B	2.84%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	150.33	120.26	$371.29B	2.65%	-	34.70%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	397.14	25.54	$356.47B	2.33%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	159.99	24.20	$304.10B	3.03%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	162.70	24.36	$252.33B	1.98%	15.97%	21.96%	9.82%	45.96%
9	AMGN Amgen Inc. NDXSPXR3KPHARMA	437.23	27.14	$235.98B	2.49%	13.95%	91.47%	5.51%	5.55%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	93.86M	415.48M	84.51M	666.65M	239.24M	70.44M	147.14M	139.51M	56.70M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14.12M	15.32M	21.50M	22.10M	30.70M	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	652.54M	223.91M	48.95M	125.03M	108.82M	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	137.03M	122.84M	129.93M	110.00M	124.25M	-
Operating Income	-20.82M	-33.20M	-	-75.26M	-76.50M	-63.31M	-	-40.83M	-41.47M	-41.63M	-	-43.51M	-41.99M	-41.90M	-	-40.22M	-36.67M	-14.99M	-	-22.90M	-17.03M	-193.94M	-208.63M	-345.83M	-307.14M	209.29M	-482.96M	-127.19M	-312.77M	55.46M	-125.63M	-144.83M	161.00M	-134.02M	515.51M	101.07M	-80.98M	15.04M	-15.43M	-54.91M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	533.91M	120.53M	-190.97M	28.85M	-543.00K	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.72M	5.52M	5.48M	5.82M	4.90M	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	519.85M	107.45M	-203.04M	17.90M	-8.51M	-
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.20M	946.00K	-657.00K	376.00K	985.00K	-
Net Income	-20.64M	-33.12M	-78.81M	-77.25M	-79.35M	-66.25M	-57.11M	-43.85M	-44.47M	-44.61M	-50.84M	-46.35M	-44.49M	-44.57M	-49.33M	-43.22M	-39.60M	-18.04M	-31.83M	-25.86M	-17.52M	-197.31M	-222.72M	-352.32M	-322.43M	203.41M	-510.49M	-168.61M	-293.90M	58.01M	-130.78M	-147.55M	162.38M	-121.30M	518.65M	106.51M	-202.38M	17.53M	-9.49M	-53.39M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.30	-3.21	-3.05	-4.75	-4.31	2.56	-6.53	-2.15	-3.41	0.58	-1.26	-1.05	0.99	-0.76	2.93	0.62	-1.25	0.11	-0.06	-0.32
R&D Expense	27.73M	30.66M	-	68.95M	64.90M	52.98M	-	37.65M	39.26M	41.86M	-	44.51M	44.54M	41.33M	-	35.47M	30.42M	18.61M	-	16.89M	34.85M	294.09M	592.67M	570.68M	408.19M	383.48M	289.65M	304.30M	247.10M	219.47M	106.23M	92.68M	106.95M	87.16M	88.94M	79.23M	98.27M	-	95.47M	70.69M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	343.00K	14.69M	22.08M	20.91M	30.66M	36.25M	15.35M	31.18M	34.29M	18.66M	475.60M	-	1.60B	556.38M	682.16M	1.12B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	902.64M	343.77M	202.74M	73.04M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	696.31M	212.61M	479.42M	1.05B
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	1.34B	779.12M	728.35M	499.80M
Operating Income	-37.38M	-38.49M	-21.58M	-29.66M	-52.43M	-83.69M	-157.24M	-269.11M	-171.71M	-173.92M	-120.58M	-416.72M	-	-644.74M	-566.51M	-248.93M	550.64M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-604.71M	-487.39M	-108.04M	492.33M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	19.88M	14.42M	20.07M	22.55M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-653.65M	-543.03M	-176.62M	442.17M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	4.29M	2.03M	10.88M	1.86M
Net Income	-40.35M	-35.71M	-19.36M	-28.51M	-51.98M	-82.95M	-156.94M	-279.97M	-183.77M	-184.75M	-132.69M	-418.26M	-	-657.94M	-545.06M	-187.50M	440.30M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-5.51	-7.27	-	-8.42	-5.41	-1.23	2.58
R&D Expense	25.78M	28.03M	18.36M	26.91M	58.53M	94.42M	162.64M	237.94M	168.44M	173.80M	113.84M	747.03M	2.53B	1.24B	737.50M	391.17M	342.32M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	74.84M	66.58M	102.34M	235.12M	276.00M	386.04M	394.30M	302.49M	207.98M	172.96M	1.58B	-	2.26B	1.80B	1.56B	1.18B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.70B	1.14B	1.13B	978.28M
Cash & Equivalents	26.94M	38.76M	8.06M	14.10M	17.40M	119.47M	32.34M	93.11M	144.35M	106.31M	70.15M	78.82M	553.40M	-	1.34B	568.50M	530.23M	240.63M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	36.68M	41.70M	8.75M	11.54M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	82.38M	297.24M	108.28M	106.45M
Total Liabilities	-	-	15.79M	12.73M	22.11M	31.89M	46.38M	93.37M	399.85M	404.23M	375.91M	358.97M	955.27M	-	2.89B	2.51B	2.18B	1.30B
Current Liabilities	-	-	10.27M	7.58M	11.68M	18.12M	34.12M	76.49M	66.41M	73.67M	45.54M	25.80M	579.67M	-	2.46B	1.64B	1.15B	459.95M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	166.47M	168.02M	169.68M	244.21M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	549.78M	229.08M	230.42M	248.81M
Total Equity	42.95M	69.95M	59.05M	53.85M	80.24M	203.23M	229.62M	292.67M	-5.55M	-101.73M	-167.94M	-186.02M	627.21M	-	-634.08M	-716.93M	-623.84M	-127.75M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	86.81M	140.51M	161.94M	164.97M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-32.83M	-32.85M	-23.63M	-18.23M	-126.09M	-258.77M	-144.48M	-184.82M	-136.62M	-42.54M	322.95M	-415.94M	-713.97M	-87.26M	-244.63M
Investing Cash Flow	2.35M	-21.27M	18.54M	-32.26M	-21.27M	28.02M	35.97M	28.60M	38.49M	-377.78M	100.15M	-92.98M	-58.81M	-204.04M	-78.27M
Financing Cash Flow	42.29M	23.43M	11.13M	53.79M	208.28M	279.85M	64.54M	102.81M	98.38M	984.76M	461.71M	324.99M	4.47M	260.58M	27.74M

Ratios (Annual)

Figures in %.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	43.5%	38.2%	70.3%	93.5%
Operating Margin %	-	-11,222.7%	-146.9%	-134.4%	-250.7%	-273.0%	-433.8%	-1,752.8%	-550.8%	-507.2%	-646.1%	-87.6%	-	-40.3%	-101.8%	-36.5%	49.0%
Net Margin %	-	-10,410.5%	-131.8%	-129.1%	-248.5%	-270.5%	-432.9%	-1,823.5%	-589.5%	-538.8%	-711.0%	-87.9%	-	-41.1%	-98.0%	-27.5%	39.2%
ROE %	-57.7%	-60.5%	-36.0%	-35.5%	-25.6%	-36.1%	-53.6%	5,048.1%	180.6%	110.0%	71.3%	-66.7%	-	103.8%	76.0%	30.1%	-344.7%
ROCE %	-	-59.6%	-36.6%	-32.7%	-24.2%	-34.6%	-50.8%	-82.1%	-75.0%	-107.1%	-81.9%	-41.6%	-	320.3%	-348.9%	-61.3%	76.8%

Shareholding Pattern

Insiders

5.06%

Institutions

69.01%

Public Float

72.69%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Shah Capital Management	8.59%	14.17M	$131.17M
2	Blackrock Inc.	8.46%	13.95M	$129.15M
3	State Street Corporation	7.12%	11.74M	$108.72M
4	Vanguard Portfolio Management LLC	4.61%	7.61M	$70.45M
5	Vanguard Capital Management LLC	4.40%	7.26M	$67.20M
6	Sanofi	4.17%	6.88M	$63.71M
7	Shaw D.E. & Co., Inc.	3.43%	5.65M	$52.33M
8	Geode Capital Management, LLC	2.55%	4.21M	$38.96M
9	Two Sigma Investments, LP	2.48%	4.09M	$37.88M
10	Coatue Management LLC	2.33%	3.84M	$35.53M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for NVAX

Google News Mon, 07 Sep 2026

GOOGL Stock Price Today - Alphabet Inc Class A News, Charts, Retail Sentiment - Stocktwits

<a href="https://news.google.com/rss/articles/CBMiS0FVX3lxTE5GV3FIb3o4T1ZMbUZxeGdxTXBNenlYM1FQWWt5X1EySTNJYU9keEN1Y3lFTVYzQTVQUDJTRmR2OUtvOENRbkM0M2dQYw?oc=5" target="_blank">GOOGL Stock Price Today - Alphabet Inc Class A News, Charts, Reta…

Google News Sat, 05 Sep 2026

Novavax Stock Price Forecast. Should You Buy NVAX? - StockInvest.us

<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE1xRWJjX3ByNnNQNDVya3RoSjNwbWxWRmdoSEJzeFE2T2ZLRFVka28zVXZQMFdwR2NWTHpmOEVKRDdBVmRLeFROYw?oc=5" target="_blank">Novavax Stock Price Forecast. Should You Buy NVAX?</a>  <fo…

Google News Wed, 19 Aug 2026

Novavax (NVAX) Shares Skyrocket, What You Need To Know - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQLWJkQlAydUdnS3A0ekRNeThPVTRTUkU5LW1TYktGWFJpOWFfdjROTWxBLUlna0cxWkJyUmRNYVhNQnRJVUhDZEpwdE9BYXVkdWdIRF85dUgtRFY1WFVXVmtuNzFuYzJqQkVycHpveU93VUdiYWZuLUVpTW9Sd2loVWVWUl9CM0FpdDF3Nz…

Google News Sun, 06 Sep 2026

NVAX Form 4 Filings - Novavax Inc SEC Form 4 - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE9RR0FTSXBZUHpGWnozbDR4ZE5mb2tzcVZHcXpFNzFuYkdvX1ZiaWJucUdJb21SVEZKaERoSGQ0Rktja1dEUDFDNGVCWGd3akhGZDZCMXJJY3VlQnB3OF9KaHg4ZGJMUQ?oc=5" target="_blank">NVAX Form 4 Filings - Novavax…

Google News Fri, 21 Aug 2026

NVAX Stock Alert: Biotechs Hit Post-Pandemic High on mRNA Cancer Breakthrough - Barchart.com

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNekIxbndyM1JGY3lkSWlXUEhUcHhUeWFmRkVOWnk0NVhYWE4yZHdVT1ZGZU40TFpCNXRzd05DMlBMY1AyMXAtNWUzTWw1S0VyLTlXbTAzd3BJUkVsQ2JhRnkxSkFqYWhEempjZENIcDJJZzJJZTBBOWh5MW5ZVFlwQUpNenhiWFc0Mk1iVk…

Google News Sun, 06 Sep 2026

Why Novavax (NVAX) Is Up 10.4% After New XFG-Targeted Nuvaxovid Approvals Expand Partner-Led Reach - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxOaXU0eUpGU2RDVmtLSUl4azh3M0JhQjAwQnhXeS1FX0xtdV8wYTBxVWxEdUpmZE82MTl2X0R2ZC03Ynl2UFJkaEJyRlZ2aTBJRUdHM0pjeXI5Q25rZ0ZHdGVTR0ZuSDNoMm9ZeHNCaTVhczV4RDUxMFhpby1uR0o4aS0tRXdOTjZWWWs1WT…

NVAX — Frequently Asked Questions

What is the current share price of Novavax, Inc. (NVAX)?

As of 2026-09-07 16:24 PDT, Novavax, Inc. (NVAX) trades at $10.22 on NasdaqGS. Its 52-week range is $6.22 to $11.19.

What is the market capitalisation of NVAX?

Novavax, Inc. (NVAX) has a market capitalisation of $1.69B on NasdaqGS.

What is the P/E ratio of NVAX?

NVAX trades at a trailing price-to-earnings (P/E) ratio of -18.25. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is -9.03.

Is NVAX a good stock to buy?

This page provides a data-driven analysis of Novavax, Inc. (NVAX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Novavax, Inc. NVAX R2KR3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

GOOGL Stock Price Today - Alphabet Inc Class A News, Charts, Retail Sentiment - Stocktwits

Novavax Stock Price Forecast. Should You Buy NVAX? - StockInvest.us

Novavax (NVAX) Shares Skyrocket, What You Need To Know - Yahoo Finance

NVAX Form 4 Filings - Novavax Inc SEC Form 4 - Stock Titan

NVAX Stock Alert: Biotechs Hit Post-Pandemic High on mRNA Cancer Breakthrough - Barchart.com

Why Novavax (NVAX) Is Up 10.4% After New XFG-Targeted Nuvaxovid Approvals Expand Partner-Led Reach - simplywall.st

NVAX — Frequently Asked Questions

What is the current share price of Novavax, Inc. (NVAX)?

What is the market capitalisation of NVAX?

What is the P/E ratio of NVAX?

Is NVAX a good stock to buy?

Explore More